1 citations
,
November 2021 in “Société internationale d'urologie journal” This review discusses the impact of COVID-19 on lower urinary tract symptoms and benign prostatic enlargement, noting altered patient care and management, but provides no new clinical results.
March 2025 in “MAEDICA – a Journal of Clinical Medicine” This review explores the potential impact of SARS-CoV-2 on benign prostatic hyperplasia and related lower urinary tract symptoms but reports no new clinical results, emphasizing the need for further studies to quantify these changes.
21 citations
,
May 2021 in “Prostate Cancer and Prostatic Diseases” This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.
September 2010 in “Zhonghua miniao waike zazhi” This study found that long-term administration of tamsulosin hydrochloride 0.2 mg is effective, safe, and well-tolerated for improving symptoms and quality of life in patients with LUTS of BPH.
December 2016 in “The journal of sexual medicine” This study found that 63.8% of patients with lower urinary tract symptoms due to benign prostatic hyperplasia were undiagnosed with erectile dysfunction, and a significant majority responded positively to treatment.